✦ LIBER ✦

794 ORAL Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RANDOMISED PHASE III TRIAL OF THE MULTIK

✍ Escudier, B.; Szczylik, C.; Eisen, T.; Oudard, S.; Stadler, W.M.; Schwartz, B.; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

795 ORAL Phase II trial of sorafenib (BA

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 273 KB

4506 ORAL A large open-label, non-compar

✍ Beck, J.; Bajetta, E.; Escudier, B.; Negrier, S.; Keilholz, U.; Szczylik, C.; Me 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A LARGE OPEN-LABEL, NON-COMPARATIVE, PHA

✍ J. Beck; E. Verzoni; S. Negrier; U. Keilholz; C. Szczylik; S. Bracarda; C. Bokem 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

883 POSTER Phase I trial of sorafenib (B

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

7130 Efficacy and safety of sorafenib in

✍ Bukowski, R.; Eisen, T.E.; Stadler, W.S.; Szczylik, C.S.; Oudard, O.S.; Siebels, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB